• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性免疫缺陷病个体中脊髓灰质炎病毒的长期排泄:世界卫生组织登记处分析

Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.

作者信息

Macklin Grace, Liao Yi, Takane Marina, Dooling Kathleen, Gilmour Stuart, Mach Ondrej, Kew Olen M, Sutter Roland W

机构信息

World Health Organization, Geneva, Switzerland.

University of Tokyo, Tokyo, Japan.

出版信息

Front Immunol. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103. eCollection 2017.

DOI:10.3389/fimmu.2017.01103
PMID:28993765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5622164/
Abstract

Individuals with primary immunodeficiency disorder may excrete poliovirus for extended periods and will constitute the only remaining reservoir of virus after eradication and withdrawal of oral poliovirus vaccine. Here, we analyzed the epidemiology of prolonged and chronic immunodeficiency-related vaccine-derived poliovirus cases in a registry maintained by the World Health Organization, to identify risk factors and determine the length of excretion. Between 1962 and 2016, there were 101 cases, with 94/101 (93%) prolonged excretors and 7/101 (7%) chronic excretors. We documented an increase in incidence in recent decades, with a shift toward middle-income countries, and a predominance of poliovirus type 2 in 73/101 (72%) cases. The median length of excretion was 1.3 years (95% confidence interval: 1.0, 1.4) and 90% of individuals stopped excreting after 3.7 years. Common variable immunodeficiency syndrome and residence in high-income countries were risk factors for long-term excretion. The changing epidemiology of cases, manifested by the greater incidence in recent decades and a shift to from high- to middle-income countries, highlights the expanding risk of poliovirus transmission after oral poliovirus vaccine cessation. To better quantify and reduce this risk, more sensitive surveillance and effective antiviral therapies are needed.

摘要

原发性免疫缺陷病患者可能会长期排泄脊髓灰质炎病毒,在口服脊髓灰质炎疫苗根除和停用后,他们将成为仅存的病毒储存宿主。在此,我们分析了世界卫生组织维护的一个登记册中与免疫缺陷相关的长期和慢性疫苗衍生脊髓灰质炎病毒病例的流行病学情况,以确定风险因素并确定排泄时长。1962年至2016年期间,共有101例病例,其中94/101(93%)为长期排泄者,7/101(7%)为慢性排泄者。我们记录到近几十年来发病率有所上升,病例向中等收入国家转移,并且在73/101(72%)的病例中2型脊髓灰质炎病毒占主导。排泄的中位时长为1.3年(95%置信区间:1.0,1.4),90%的个体在3.7年后停止排泄。常见变异型免疫缺陷综合征和居住在高收入国家是长期排泄的风险因素。病例流行病学的变化,表现为近几十年来发病率更高以及从高收入国家向中等收入国家转移,凸显了口服脊髓灰质炎疫苗停用后脊髓灰质炎病毒传播风险的扩大。为了更好地量化和降低这种风险,需要更敏感的监测和有效的抗病毒疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/b19eb6eee1ff/fimmu-08-01103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/4bae9d4c8136/fimmu-08-01103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/5c5deca4583b/fimmu-08-01103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/b19eb6eee1ff/fimmu-08-01103-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/4bae9d4c8136/fimmu-08-01103-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/5c5deca4583b/fimmu-08-01103-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afef/5622164/b19eb6eee1ff/fimmu-08-01103-g003.jpg

相似文献

1
Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.原发性免疫缺陷病个体中脊髓灰质炎病毒的长期排泄:世界卫生组织登记处分析
Front Immunol. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103. eCollection 2017.
2
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.免疫缺陷相关的长期疫苗衍生脊髓灰质炎病毒排泄者患病率建模及抗病毒药物的潜在益处
BMC Infect Dis. 2015 Sep 17;15:379. doi: 10.1186/s12879-015-1115-5.
3
Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication.原发性免疫缺陷患者是脊髓灰质炎病毒的储存宿主,对根除脊髓灰质炎构成风险。
Front Immunol. 2017 Jun 13;8:685. doi: 10.3389/fimmu.2017.00685. eCollection 2017.
4
The Molecular Evolution of Type 2 Vaccine-Derived Polioviruses in Individuals with Primary Immunodeficiency Diseases.2 型疫苗衍生脊髓灰质炎病毒在原发性免疫缺陷病个体中的分子进化。
Viruses. 2021 Jul 20;13(7):1407. doi: 10.3390/v13071407.
5
Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Infections: A Review of Epidemiology and Progress in Detection and Management.免疫缺陷相关疫苗衍生脊髓灰质炎病毒(iVDPV)感染:流行病学及检测与管理进展综述
Pathogens. 2024 Dec 20;13(12):1128. doi: 10.3390/pathogens13121128.
6
Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.免疫缺陷相关的疫苗衍生脊髓灰质炎病毒(iVDPV)病例:一项系统综述及对脊髓灰质炎根除的影响
Vaccine. 2015 Mar 3;33(10):1235-42. doi: 10.1016/j.vaccine.2015.01.018. Epub 2015 Jan 16.
7
Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.免疫缺陷相关疫苗衍生脊髓灰质炎病毒的全面筛查:一项至关重要的口服脊髓灰质炎疫苗停用风险管理策略。
Epidemiol Infect. 2017 Jan;145(2):217-226. doi: 10.1017/S0950268816002302. Epub 2016 Oct 20.
8
New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data.免疫缺陷相关疫苗衍生脊髓灰质炎病毒感染的病理生理学新见解;对超过 50 年数据的系统回顾。
Vaccine. 2018 Mar 20;36(13):1711-1719. doi: 10.1016/j.vaccine.2018.02.059. Epub 2018 Feb 23.
9
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.用于预防脊髓灰质炎的序贯灭活脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎减毒活疫苗(OPV)
Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2.
10
Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication.原发性免疫缺陷病患者接种口服脊髓灰质炎减毒活疫苗后的病毒排泄情况:根除脊髓灰质炎终局计划中的临床医生观点
BMC Res Notes. 2018 Oct 11;11(1):717. doi: 10.1186/s13104-018-3822-7.

引用本文的文献

1
Public health response to immunodeficiency-related vaccine-derived poliovirus during a poliovirus outbreak in the Philippines: a case report.菲律宾脊髓灰质炎病毒爆发期间对免疫缺陷相关疫苗衍生脊髓灰质炎病毒的公共卫生应对:病例报告
IJID Reg. 2025 Aug 7;16:100722. doi: 10.1016/j.ijregi.2025.100722. eCollection 2025 Sep.
2
Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Infections: A Review of Epidemiology and Progress in Detection and Management.免疫缺陷相关疫苗衍生脊髓灰质炎病毒(iVDPV)感染:流行病学及检测与管理进展综述
Pathogens. 2024 Dec 20;13(12):1128. doi: 10.3390/pathogens13121128.
3
Immunodeficiency-Related Vaccine-Derived Poliovirus (iVDPV) Excretion in an Infant with Severe Combined Immune Deficiency with Spillover to a Parent.

本文引用的文献

1
Antiviral Activity of Pocapavir in a Randomized, Blinded, Placebo-Controlled Human Oral Poliovirus Vaccine Challenge Model.泊卡帕韦在随机、双盲、安慰剂对照的口服脊髓灰质炎病毒疫苗激发模型中的抗病毒活性
J Infect Dis. 2017 Feb 1;215(3):335-343. doi: 10.1093/infdis/jiw542.
2
Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.免疫缺陷相关疫苗衍生脊髓灰质炎病毒的全面筛查:一项至关重要的口服脊髓灰质炎疫苗停用风险管理策略。
Epidemiol Infect. 2017 Jan;145(2):217-226. doi: 10.1017/S0950268816002302. Epub 2016 Oct 20.
3
Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995-2014.
一名患有严重联合免疫缺陷的婴儿排出与免疫缺陷相关的疫苗衍生脊髓灰质炎病毒(iVDPV)并传播给其父母。
Vaccines (Basel). 2024 Jul 9;12(7):759. doi: 10.3390/vaccines12070759.
4
Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020-2024.支持全球消灭脊髓灰质炎的脊髓灰质炎病毒传播综述与经济建模:2020 - 2024年
Pathogens. 2024 May 22;13(6):435. doi: 10.3390/pathogens13060435.
5
Population Immunity and Polio Eradication.群体免疫与脊髓灰质炎根除
Pathogens. 2024 Feb 20;13(3):183. doi: 10.3390/pathogens13030183.
6
Health Economic Analysis of Antiviral Drugs in the Global Polio Eradication Endgame.全球消灭脊灰行动后期抗病毒药物的卫生经济学分析。
Med Decis Making. 2023 Oct-Nov;43(7-8):850-862. doi: 10.1177/0272989X231191127. Epub 2023 Aug 14.
7
Assessment of Enterovirus Excretion and Identification of VDPVs in Patients with Primary Immunodeficiency in India: Outcome of ICMR-WHO Collaborative Study Phase-I.印度原发性免疫缺陷患者肠道病毒排泄情况评估及疫苗衍生脊髓灰质炎病毒鉴定:印度医学研究理事会-世界卫生组织合作研究第一阶段成果
Vaccines (Basel). 2023 Jul 6;11(7):1211. doi: 10.3390/vaccines11071211.
8
The Fight against Poliovirus Is Not Over.对抗脊髓灰质炎病毒的斗争尚未结束。
Microorganisms. 2023 May 17;11(5):1323. doi: 10.3390/microorganisms11051323.
9
Asymptomatic immunodeficiency-associated vaccine-derived poliovirus infections in two UK children.两名英国儿童无症状免疫缺陷相关疫苗衍生脊髓灰质炎病毒感染。
Nat Commun. 2023 Jun 9;14(1):3413. doi: 10.1038/s41467-023-39094-0.
10
Poliovirus surveillance in patients with primary immunodeficiencies, India.印度原发性免疫缺陷病患者的脊髓灰质炎病毒监测。
Bull World Health Organ. 2023 May 1;101(5):346-354. doi: 10.2471/BLT.22.289066.
疫苗衍生脊髓灰质炎病毒与原发性免疫缺陷儿童,伊朗,1995 - 2014年
Emerg Infect Dis. 2016 Oct;22(10):1712-9. doi: 10.3201/eid2210.151071.
4
Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.三价口服脊髓灰质炎疫苗停用和灭活脊髓灰质炎疫苗引入-全球,2016 年。
MMWR Morb Mortal Wkly Rep. 2016 Sep 9;65(35):934-8. doi: 10.15585/mmwr.mm6535a3.
5
Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs.免疫缺陷相关的长期疫苗衍生脊髓灰质炎病毒排泄者患病率建模及抗病毒药物的潜在益处
BMC Infect Dis. 2015 Sep 17;15:379. doi: 10.1186/s12879-015-1115-5.
6
Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.免疫缺陷个体中脊髓灰质炎病毒复制28年:对全球根除脊髓灰质炎行动的影响
PLoS Pathog. 2015 Aug 27;11(8):e1005114. doi: 10.1371/journal.ppat.1005114. eCollection 2015 Aug.
7
Immunodeficiency-related vaccine-derived poliovirus (iVDPV) cases: a systematic review and implications for polio eradication.免疫缺陷相关的疫苗衍生脊髓灰质炎病毒(iVDPV)病例:一项系统综述及对脊髓灰质炎根除的影响
Vaccine. 2015 Mar 3;33(10):1235-42. doi: 10.1016/j.vaccine.2015.01.018. Epub 2015 Jan 16.
8
Possible eradication of wild poliovirus type 3--worldwide, 2012.2012年全球范围内3型野生脊髓灰质炎病毒可能被根除。
MMWR Morb Mortal Wkly Rep. 2014 Nov 14;63(45):1031-3.
9
Progress in the development of poliovirus antiviral agents and their essential role in reducing risks that threaten eradication.在开发抗脊灰病毒药物方面取得的进展及其在降低威胁消除工作的风险方面的重要作用。
J Infect Dis. 2014 Nov 1;210 Suppl 1:S447-53. doi: 10.1093/infdis/jiu043.
10
Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series.原发性免疫缺陷病患者中的脊髓灰质炎病毒排出:七国研究系列总结。
J Infect Dis. 2014 Nov 1;210 Suppl 1:S368-72. doi: 10.1093/infdis/jiu065.